Skip to main content
Fig. 1 | Diabetology & Metabolic Syndrome

Fig. 1

From: Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseases

Fig. 1

Evidence-based algorithm for the management of patients with T2DM and high risk of CVD. CVD cardiovascular disease, GLP-1 glucagon-like peptide-1, SGLT2 sodium–glucose transporter proteins-2, TZD thiazolidinedione, DPP4 dipeptidylpeptidase-4. aProven CVD benefits means the agent has a label indication of reducing the CVD events. For SGLT2 inhibitors evidence based preference is empagliflozin > canagliflozin. SGLT2 inhibitors vary in regards to eGFR pre-requisites for a continued use. bFor GLP-1 agonist evidence based preference is Semaglutide > Liraglutide > Dulaglutide > Exenatide > Lixenatide. Caution to be exercised in case of end-stage renal disease. cDegludec and insulin Glargine (U100) have shown CVD safety, dDapagliflozin: preferred option for patients with eGFR > 60 mL/min/1.73 m2, eLow dose TZDs are better tolerated. fChoose later generation SU to minimize the risk of hypoglycaemia

Back to article page